Requests that the require any application submitted under sections 505(j) or 505(b)(2) of the FD&C Act that references AMVUTTRA® as the RLD to include sufficient evidence to demonstrate pharmaceutical equivalence7 and to establish that the proposed product can be expected to have the same clinical effect and safety profile as AMVUTTRA® under the conditions of use described in the labeling.